Plasmalogen is a class of ether phospholipid that Japanese researchers have studied and commercialised as a brain-health ingredient for over a decade, most often purified from scallops. Brands abroad ask for it because it is a Japanese-developed ingredient with a track record of human trials behind it, unlike many newer “focus” ingredients.
This guide is for brand owners planning a plasmalogen product made in Japan. It covers what the human trials show, who paid for them, Japan’s regulatory framing, how the ingredient is usually formulated, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a plasmalogen product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
Small Japanese trials in healthy adults have reported benefits for verbal memory and mental concentration at very low daily doses, while a larger trial in a mixed population found a benefit only in a subgroup.
| Study | Design | Reported result |
|---|---|---|
| Randomised, double-blind, placebo-controlled trial, Frontiers in Nutrition 2026 (PMID 42656342) | 68 Japanese adults aged 40+ with below-average verbal memory; 1 mg/day scallop-derived plasmalogen or placebo for 12 weeks | Standardised verbal memory score improved significantly more with plasmalogen than placebo (p = 0.042); exploratory analyses also suggested improvement in selected attention-related domains |
| Randomised, double-blind, placebo-controlled trial, Frontiers in Cell and Developmental Biology 2022 (PMID 35721497) | 40 college athletes; 2 mg/day scallop-derived plasmalogen or placebo for 4 weeks | Plasmalogen group had significantly lower anger-hostility and fatigue-inertia mood scores, and significantly better mental-concentration test performance, than placebo |
| Multicentre, randomised, double-blind, placebo-controlled trial, EBioMedicine 2017 (PMID 28259590) | 328 adults aged 60–85 with mild Alzheimer’s disease or mild cognitive impairment (MMSE-J score 20–27); 1 mg/day scallop-derived plasmalogen or placebo for 24 weeks | No significant difference across the full study group; a memory score improved significantly in the subgroup with mild Alzheimer’s disease, with a larger effect in women and participants under 77 |
Three points to keep in view:
- Population. The largest trial studied adults already diagnosed with mild Alzheimer’s disease or mild cognitive impairment, and its overall result was not significant — only a subgroup improved. That is a fact about the research, not a basis for a product claim about any disease.
- Dose and duration. All three trials used low daily amounts (1–2 mg) over 4–24 weeks. None followed participants for longer.
- Funding. The 2026 trial disclosed that two authors held an executive, ownership or employment relationship with the supplement’s manufacturer. The 2017 trial was funded by a Japanese research society dedicated to plasmalogen. The 2022 trial declared no competing interests.
Checked against the published abstracts on 25 September 2026.
What Japanese products say
Plasmalogen appears in Japan’s Foods with Function Claims system, notified for functions related to maintaining memory in healthy adults.
Under the Foods with Function Claims system, the notifying business is responsible for the scientific evidence behind its stated function and submits it to the Consumer Affairs Agency before sale. Several plasmalogen products have been notified this way, with wording that describes maintaining a normal, healthy level of memory function — not treating or reversing any diagnosed condition.
Two lessons for a brand abroad:
- The Japanese wording covers healthy-adult memory maintenance, not disease. The mixed-population trial above is research context, never a basis for disease-related wording on a product.
- A Japanese notification is not a global endorsement. It is a Japanese regulatory mechanism for products sold in Japan. Your label abroad follows your own market’s rules.
💬 Need an evidence summary for your regulatory adviser that separates Japanese notifications from the underlying trials? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe plasmalogen by what was studied in healthy adults, never by the disease population in the largest trial.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for verbal memory and mental concentration in healthy adults” | Names of any cognitive disease or “treats”, “reverses” or “prevents” decline |
| ”Contains 1 mg plasmalogen per daily serving" | "Clinically proven” without naming the study and its limits |
| ”Small, early trials; larger studies are still needed” | Implying the mixed-population trial’s subgroup result applies to the general population |
How plasmalogen is formulated
Plasmalogen is dosed in single milligrams and is sensitive to oxidation, so the specification has to protect it as much as measure it.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Soft capsule | Protects an oil-based, oxidation-sensitive ingredient | Shell material and dietary suitability |
| Hard capsule with oil fill or powder blend | Simple, flavourless | Needs an antioxidant-compatible fill |
Decisions that shape the specification:
- Source. Plasmalogen for foods is most often purified from scallops; other marine or animal sources exist. Ask the supplier for the source species and the purification method.
- Amount per serving. Match the amount to a study you intend to cite — 1 mg/day appears in more than one trial above.
- Stability. Plasmalogen’s ether-linked structure is prone to oxidation. Antioxidant companions, oxygen-barrier packaging and storage guidance all affect shelf life.
- Companion ingredients. Plasmalogen is sometimes combined with other “brain and focus” ingredients. Each needs its own check against Japanese food law.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Scallop-derived plasmalogen is an established food ingredient in Japan with existing Foods with Function Claims notifications. Companion botanicals in a combined “brain and focus” formula need their own check, since some botanicals sold freely elsewhere are treated as medicines in Japan. See the Japan-made supplement OEM page, and compare with our NMN and GABA guides if you are building a combined formula.
Before you ask for a quotation
A factory can quote accurately once the source, the amount, the form and the packaging are fixed.
- Plasmalogen source and purification method
- Amount per serving and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Packaging and stability requirements (oxidation)
- Countries you will sell in, and first order and annual volume
💬 Ready to design a Japan-made plasmalogen product? Send us the concept — source, amount, form and the countries you will sell in.
Frequently asked questions
1. Does plasmalogen improve memory?
A 2026 trial in 68 healthy adults with below-average verbal memory found a significant improvement with 1 mg/day scallop-derived plasmalogen over 12 weeks. Describe it as studied for verbal memory in healthy adults, not as a proven memory treatment.
2. Was plasmalogen tested in people with cognitive decline?
Yes, one 2017 trial studied adults with mild Alzheimer’s disease or mild cognitive impairment. The overall result across the full group was not significant; only a subgroup improved. This is research context, not a basis for disease-related product claims.
3. What dose do the human trials use?
Very small amounts — 1–2 mg a day in the trials above, taken for 4 to 24 weeks.
4. Where does plasmalogen for supplements come from?
Most Japanese trials and products use plasmalogen purified from scallops. Ask your supplier for the exact source and purification method.
5. Is plasmalogen permitted in Japanese foods?
Yes. Scallop-derived plasmalogen is an established food ingredient in Japan, with existing Foods with Function Claims notifications for healthy-adult memory maintenance.
Sources: “Orally administered scallop-derived plasmalogens improve cognitive function in healthy middle-aged and older adults: a randomized, double-blind, placebo-controlled trial”, Frontiers in Nutrition 2026 (PMID 42656342); “Orally Administered Plasmalogens Alleviate Negative Mood States and Enhance Mental Concentration: A Randomized, Double-Blind, Placebo-Controlled Trial”, Frontiers in Cell and Developmental Biology 2022 (PMID 35721497); “Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer’s Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial”, EBioMedicine 2017 (PMID 28259590); Consumer Affairs Agency notifications for Foods with Function Claims. Checked on 25 September 2026.